Asia-Pacific specialist CRO Novotech has been invited to share the advantages of conducting clinical trials in Australia and the Asia-Pacific, at the 37th Annual J.P.Morgan Healthcare Conference (7 -10 January 2019).

The presentation, Australia's R&D Refund and Simplified Regulatory Environment as Gateway to Asia features Novotech CEO Dr John Moller and Novotech’s industry partners in Biotech Connect the single access point to Australia’s clinical trial environment - CoSec Consulting CEO Blair Lucas, and Nucleus Network CEO Cameron Johnson

Dr Moller will share the latest data on clinical trial activity in Australia, which is up by 11% to 810 on 2017, and Asia-Pacific trial numbers which is up by 10% to 7,715 trials.

In line with the increase in activity in the region, Novotech’s clinical staff numbers in Asia have grown by more than 20% during the last quarter of 2018.

Dr Moller said the Novotech growth is fueled by demand for a regional CRO with international accreditation and reputation, combined with local knowledge, partnerships and expertise.

He will present data showing the rapid start-up speed, low cost and high quality on offer in Australia, and how Novotech can then support later Phase studies in the Asia-Pacific.

“The Novotech team is well positioned across the region to access the more than 1.4 billion people living in urban areas, which is a key factor in the decision by biotechs to include the Australia and the Asia-Pacific in their global studies,” he said.

Novotech, which has 11 offices in the region, now has over 550 employees through-out Australia, New Zealand and Asia.

Novotech works in partnership with the leading medical institutions across Asia to accelerate quality clinical research for its clients, and has now signed 10 strategic partnerships with hospitals and research institutions in the region.

Novotech has acquired Australasian specialist CRO Clinical Network Services (CNS) as part of a mutual mission to expand services to biopharma for early phase product development and clinical research in Australia, through to later Phase regional and global trials.

The J.P.Morgan presentation includes the many compelling reasons to consider Asia-Pacific for clinical research:

  • Large patient population
  • Few competing trials
  • Efficient regulatory system
  • Highly qualified and educated medical professionals
  • Low operational costs
  • Well supported IT infrastructure
  • High level of GCP compliance
  • Efficient trial management and logistics infrastructure

 “Our in-country relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets,” said Dr Moller.

Novotech has offices in 11 countries across the region, and MOUs with major health providers.


About Novotech -
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region. 

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners. 


For RFP enquiries: Please fill out the form available at

기타 관련 콘텐츠